Novavax Q3 revenue $187M (down 75% YoY); FY23 revenue guidance lowered to $900M-$1.1B

NOVAVAX INC

2023-Q3 EPS reported -$3.94 revenue$692,363,000

Q3 2023 total revenue $187M vs $735M YoY; net loss $131M improved from $169M loss YoY.
FY2023 total revenue guidance cut to $900M-$1.1B from prior $1.3B-$1.5B; expects additional $300M in Q1 2024.
Additional cost reduction of >$300M in 2024 targeting R&D/SG&A <$750M and >$100M supply network savings.
Received FDA EUA for updated COVID-19 vaccine Oct 2023; available at ~14,000 U.S. pharmacy locations.
WHO recommended R21/Matrix-M malaria vaccine; initial Matrix-M sales recognized in Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NOVAVAX INC reported the third quarter ended September 30, 2023 results: revenue $187 million, net income Net loss of $131 million.

Period: the third quarter ended September 30, 2023
Revenue: $187 million
Net income: Net loss of $131 million
Result: reported results

Exact text from the filing

received recommendation from the World Health Organization; launch expected in 2024 2 Third Quarter 2023 Financial Results • Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001000694-23-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.